NOVARTIS AG

Public Equity (NYSE)PharmaceuticalPublic EquityNYSE

📍 Basel, Switzerland• Founded 1996

StreetZero Signal 62

Be the first to signal interest

About NOVARTIS AG

Novartis AG is a Swiss multinational pharmaceutical company headquartered in Basel, Switzerland. It develops, manufactures, and markets innovative medicines in key therapeutic areas including oncology, cardiology, immunology, and neuroscience. The company is publicly listed on the New York Stock Exchange under the ticker NVS and operates globally with a focus on research-driven healthcare solutions.

LATEST FUNDINGRule 144

$933K

Announced 2026-10-28

🔒

Unlock the full deal profile

Create a free account to see investors, key highlights, news, company details and the AI analysis for NOVARTIS AG.

Create free account Sign in

Free plan includes 3 full deal profiles every month.

EMPLOYEES—

FOUNDED1996

HQBasel, Switzerland

Industry

Public Equity (NYSE)

Investors

Not disclosed in the source filing. Form D filings do not list investors — StreetZero surfaces them from news where available.

Key highlights

Completed $933,180 Rule 144 transaction
Publicly listed on NYSE
Headquartered in Basel, Switzerland
Focuses on innovative medicines across multiple therapeutic areas

Ask StreetZero about NOVARTIS AG

Put our AI to work on this deal.

What is NOVARTIS AG's value proposition?Who are NOVARTIS AG's competitors?Why does this raise matter?Summarize NOVARTIS AG for an investor.

Similar companies

Other Public Equity (NYSE) deals, ranked by Signal.

Snowflake Inc.

$94.9M

CAPITAL ONE FINANCIAL CORPORATION

Source document & SEC filing

The source SEC filing and the cached document are available to members only. Sign in to view and download them.